Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
3 clinical-grade skincare creams you really shouldn’t buy online 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Gold Slips Below $4050 as Bond Yields Surge to 4.7% on Fed Inflation Concerns – Sell Rallies at $4060 Targeting $3940 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
JPMorgan has reinstated coverage and price targets on 14 major biotechnology companies, signaling renewed confidence in the biotech sector as firms transform successful drug pipelines into profitable commercial businesses. According to analysts led by Jessica Fye, the industry is approaching a major “inflection point,” driven by improving profitability, expanding product portfolios, and upcoming clinical catalysts.
The investment bank highlighted several biotech companies that have already reached sustained profitability, including Alnylam Pharmaceuticals, BeOne Medicines, and Ascendis Pharma. Meanwhile, Insmed and Ionis Pharmaceuticals are expected to achieve profitability soon, creating opportunities for stronger margins and long-term revenue growth.
JPMorgan also emphasized the growing diversification strategies among biotech firms. Vertex Pharmaceuticals is expanding beyond its core business into renal disease treatments, while BioMarin continues strengthening its rare disease pipeline through acquisitions. Moderna is broadening the use of its mRNA technology into oncology despite ongoing financial concerns surrounding the company.
The report pointed to multiple upcoming clinical trial updates that could boost investor sentiment across the biotechnology market. Analysts expect major cardiovascular outcomes data related to Ionis-partnered therapies and important renal disease readouts from Vertex Pharmaceuticals to act as key catalysts over the next year.
JPMorgan assigned “Overweight” ratings to several biotech stocks, including Vertex Pharmaceuticals, Alnylam, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis, BioMarin, and Mirum Pharmaceuticals. Meanwhile, BioNTech, Incyte, and Halozyme received “Neutral” ratings. Moderna was rated “Underweight” due to concerns over financial risks despite progress in cancer research and mRNA development.
The bank also released updated price targets for December 2026. Vertex received a target of $515, Alnylam $420, BeOne Medicines $415, United Therapeutics $685, and Insmed $180. Moderna’s target was set at $40, while BioNTech received a $100 target.
JPMorgan believes the biotech sector is entering a period of durable expansion as companies scale beyond dependence on single products and continue building diversified, profitable healthcare franchises.
